Get startedLog in
    Picture of TG Therapeutics logo

    TGTX — TG Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapMomentum Trap
    All News

    Brief: TG Therapeutics Says Phase 3 Enhance Trial Met Its Primary Endpoint

    Picture of TG Therapeutics logoTG Therapeutics
    27/05/2026 12:44
    BRIEF-TG Therapeutics Says Phase 3 Enhance Trial Met Its Primary Endpoint
    May 27 (Reuters) - TG Therapeutics Inc TGTX.O:
    • ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ENHANCE TRIAL
    • SINGLE INFUSION SAFETY CONSISTENT WITH ESTABLISHED BRIUMVI PROFILE
    • PHASE 3 ENHANCE TRIAL SHOWS BIOEQUIVALENCE FOR SINGLE 600 MG DAY 1 BRIUMVI INFUSION
    • SUPPLEMENTAL BLA FILING FOR CONSOLIDATED BRIUMVI DOSING TARGETED FOR 2H-2026
    • SECONDARY ENDPOINTS CONSISTENT WITH PRIOR STUDIES; NO NEW SAFETY SIGNALS OBSERVED
    • PHASE 3 TRIAL MET ITS PRIMARY ENDPOINT
    Source text: ID:nGNX5PWVlt
    Further company coverage: TGTX.O

     ((Reutersbriefs@thomsonreuters.com;))

    Recent news on TG Therapeutics

    See all news